Key result
Prior VT/VF in HCM is linked to 59% 5-year survival without death or ICD discharge.
Why the study?
Prospective data on clinical outcomes in patients with HCM who survive cardiac arrest are limited, especially with modern therapies like amiodarone and ICDs.
Does low dose amiodarone or ICD therapy improve survival in HCM patients after resuscitated VT/VF?
Cohort (n=16)
Does low dose amiodarone or ICD therapy improve survival in HCM patients after resuscitated VT/VF?
No takes yet. Share an insight, caveat, or question.
In HCM patients surviving VT/VF, recurrent events are common, and ICD therapy appears to offer the best potential benefit for survival.
Elliott et al. (1999) conducted a cohort in Hypertrophic cardiomyopathy (n=16). Low dose amiodarone or implantable cardioverter defibrillators was evaluated on Cumulative survival (death or ICD discharge) at 5 years (95% CI 33-84). A history of VT/VF in patients with hypertrophic cardiomyopathy was associated with a 5-year cumulative survival (death or ICD discharge) of 59%, indicating a high risk of recurrent events.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: